Biomarkers for vascular disease . . . and other stories
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3401 (Published 10 September 2020) Cite this as: BMJ 2020;370:m3401
New biomarkers in coronary artery disease
Several novel circulating biomarkers for vascular disease have emerged recently. Examples are neutrophil gelatinase-associated lipocalin, osteoprotegerin, endostatin, YKL40, and cathepsin-B. Although individually they showed associations with heart disease and all-cause mortality, they contributed disappointingly little to the predictive value of conventional risk factors. In patients with stable coronary artery disease, the addition of data on 10 new biomarkers improved the accuracy of the prediction model by less than 2% (BMJ Open doi:10.1136/bmjopen-2019-033720).
Vaccine design
More than a hundred vaccines against SARS-CoV-2 are currently in development using a variety of technologies, some of which have not previously been used in vaccines intended for humans. Nature has a graphical guide to vaccine design, which explains the different approaches (https://www.nature.com/articles/d41586-020-01221-y). Minerva knew about vaccines derived from attenuated or inactivated viruses but was pleased to be brought up to speed on viral vector vaccines, nucleic acid vaccines, protein based vaccines, and virus-like particles.
Vaccine trials
The big question is when an effective and safe vaccine against SARS-CoV-2 will become available. Results so far have ruled out the worst case scenario that vaccines would not stimulate an immune response or that serious adverse effects would be frequent. Even so, the data are still thin. The pessimistic view is that most vaccine candidates will fail if phase III trials reveal poor efficacy or adverse effects in older people. On the other hand, if things go well, millions of doses could be available by the early weeks of 2021 (https://unherd.com/2020/08/when-will-the-covid-19-vaccine-arrive/).
Cardiovascular risk predicts cognitive decline
Participants in the Rush Memory and Ageing Project were categorised by cardiovascular risk at baseline. Followed for 20 years, those at high risk experienced the fastest decline in global cognition and memory (J Am Coll Cardiol doi:10.1016/j.jacc.2020.03.053). A subgroup had magnetic resonance imaging. Those in the highest category of vascular risk had smaller volumes of brain and hippocampus, and greater volume of white matter hyperintensities.
Infective endocarditis
A large retrospective study from Denmark investigated the risk of infective endocarditis in more than 6000 patients diagnosed with streptococcal bloodstream infections (Circulation doi:10.1161/CIRCULATIONAHA). Not surprisingly, the risk was more than three times higher in people with prosthetic valves or native valve disease. The risk also depended on the species of streptococcus. The lowest prevalence of endocarditis (1-2%) occurred in patients with S pneumoniae and S pyogenes. By contrast, endocarditis was present in almost 50% of infections with S mutans.
Survival after pulmonary resection
Despite having access to a tax funded universal health system, Swedish patients who underwent surgery for lung cancer survived longer if they were in the highest bracket of household disposable income (Thorax doi:10.1136/thoraxjnl-2019-214321). The reasons are not clear. Although patients with lower incomes had a higher prevalence of cardiovascular risk factors, the association between income and mortality remained after adjustment for differences in baseline characteristics.